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Heparan sulfate (HS) represents a major class
of glycans that perform central physiological
functions. Emerging HS and glycosaminogly-
can microarray techniques are used to interro-
gate the structure and function relationship to
develop novel therapeutic agents. Availability
of HS with specific sulfation patterns has been
a limiting factor and impedes the accuracy of
HS glycomics studies. Although organic syn-
thesis provides oligosaccharides, these may
not fully represent the biological functions of
polysaccharides. Here, we present a study for
developing an enzyme-based approach to syn-
thesize a polysaccharide library with different
sulfation patterns. Using different combinations
of biosynthetic enzymes, we synthesized eight
unique polysaccharides. We discovered that
polysaccharides without the iduronic acid resi-
due displayed strong binding affinity to anti-
thrombin and high anti-Xa and anti-IIa activities.
The enzyme-based synthetic approach could
become a general method for discovering new
HS structures with unique biological functions.
INTRODUCTION
Heparin, a commonly used anticoagulant drug, is a special
form of heparan sulfate (HS). HS or heparin contains
glucuronic/iduronic acid and glucosamine carrying sulfo
groups. A large body of evidence has demonstrated that
this highly sulfated polysaccharide plays a role in regulat-
ing embryonic development and inflammatory response
and assisting viral/bacterial infections and blood coagula-
tion [1]. The wide range of biological functions of HS
attracts considerable interest in exploiting heparin or hep-
arin-like molecules for the development of anticancer and
antiviral drugs in addition to using them for anticoagulant
purposes [2, 3]. The uniquely distributed sulfation pattern
of the HS polysaccharide is believed to regulate its func-
tional specificity [4–6]. An approach for synthesizing986 Chemistry & Biology 14, 986–993, September 2007 ª2007a polysaccharide with specific sulfation patterns will aid
in deciphering the structure and function of HS for the
development of HS-based drugs [7].
Chemical synthesis has been the major route by which
to obtain structurally defined heparin andHS oligosaccha-
rides [8]. The most important example is the synthesis
of the antithrombin-binding pentasaccharide. Currently, a
synthetic anticoagulant pentasaccharide has been mar-
keted worldwide under the trade name Arixtra. However,
chemical synthesis of nonanalog heparin and HS oligo-
saccharides, larger than hexasaccharides, is extremely
difficult, if not impossible, based on currently available
methods for carbohydrate synthesis. While a number of
groups continue to pursue the synthesis of heparin [9–11],
it has become clear that chemical synthesis with current
technology alone will be incapable of generating most
larger oligosaccharide structures. The availability of an
in vitro system bywhich to synthesize HS polysaccharides
by using biosynthetic enzymes offers a promising alterna-
tive approach [12, 13].
The biosynthesis of HS involves a series of specialized
sulfotransferases and other enzymes. Control of the sulfa-
tion pattern mainly depends on the substrate specificities
of the enzymes involved in the biosynthetic pathway. HS
is initially synthesized as a linear copolymer of glucuronic
acid (GlcUA) and N-acetylated glucosamine (GlcNAc),
which then undergoes various modifications. These
modifications are carried out by a series of biosynthetic
enzymes, including glucosaminyl N-deacetylase/N-sulfo-
transferase, which converts the GlcNAc unit to an N-sulfo
glucosamine (GlcNS) unit (Figure 1A). After the N-sulfa-
tion, C5-epimerase converts the GlcUA unit to an iduronic
acid (IdoUA) unit. The resultant polysaccharide is further
modified by 2-O-sulfotransferase (2-OST), 6-O-sulfo-
transferase (6-OST), and 3-O-sulfotransferase (3-OST) to
introduce the 2-O-sulfo group to IdoUA/GlcUA and the
6-O-sulfo/3-O-sulfo groups to the glucosamine unit, re-
spectively (Figure 1A) [14]. 6-OST is present in three iso-
forms, and 3-OST is present in seven isoforms.
In this article, we reported an enzyme-based combina-
torial approach to synthesize the polysaccharides with dif-
ferent sulfation patterns (Figure 1B). From the products,
we discovered that polysaccharides without the IdoUA
residue displayed strong binding affinity to antithrombin
and high anti-Xa and anti-IIa activities. Further, theseElsevier Ltd All rights reserved
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Enzymatic Synthesis of Heparan SulfateFigure 1. Biosynthetic Pathway of HS and the Synthetic Scheme of Polysaccharide Variants
(A) The reactions catalyzed by HS biosynthetic enzymes. The reaction sites at eachmodification step are circled. The names and abbreviations for the
saccharide units are displayed underneath the sugar unit.
(B) The steps involved in the synthesis of a library of HS-like polysaccharides. The enzymes used for each compound are shown in Table 1.polysaccharides have no activity in promoting cell prolifer-
ation, thus providing evidence for the synthesis of a func-
tionally specific anticoagulant polysaccharide. Chemical
synthesis of the IdoUA residue requires ten steps [15]. Al-
though the synthesis of IdoUA can be achieved by epim-
erase, the product contains a mixture of IdoUA and GlcUA
because the reaction catalyzed by epimerase is reversible
[16]. Consequently, the product has greater structural
heterogeneity, increasing the untoward effects of an anti-
coagulant drug. Anticoagulant polysaccharide without the
IdoUA residues could decrease the structural heterogene-
ity and reduce the complexity in the synthesis of HS-
based anticoagulant drugs. Because HS is also involved
in tumor growth and viral infections, the enzyme-based
synthetic approach could be used to prepare the HS
structures displaying anticancer and antiviral activities.
RESULTS AND DISCUSSION
In an effort to establish the synthesis of a HS polysaccha-
ride library, we have expressed essentially all HS biosyn-
thetic enzymes in Escherichia coli in large quantities [4, 7].Chemistry & Biology 14, 986–9We started the synthesis from a capsular polysaccharide
of the E. coli K5 strain, known as heparosan, which is
like a nonsulfated and unepimerized HS (Figure 1). In ad-
dition, heparosan can be converted into anticoagulant
HS by using HS biosynthetic enzymes [12, 17]. Because
N-sulfation is critical for the subsequent O-sulfations and
epimerization [18], we decided to prepare polysaccha-
rides with different types of O-sulfation patterns by using
N-sulfo heparosan as a starting material (Figure 1B). Eight
different polysaccharides that differ by the type of sulfa-
tions, such as 2-O-, 3-O-, and 6-O-sulfations, as well as
by the level of IdoUA residues, as illustrated in Figure 1B,
were prepared. The overall sulfation level among the prod-
ucts was between 0.9 and 1.4 nmoles O-sulfo groups per
microgram of polysaccharide, namely, 0.39–0.61 O-sulfo
groups per disaccharide unit, as measured based on the
specific 35S radioactivity (Table 1). Compound 6 was an
exception because it contained only 3-O-sulfation, which
is an inherently low-abundance sulfation type in the HS
isolated from a natural source [19]. Subjecting the syn-
thetic polysaccharides to an antithrombin (AT)-affinity col-
umn, we found that a significant portion of compounds 1,93, September 2007 ª2007 Elsevier Ltd All rights reserved 987
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Enzymatic Synthesis of Heparan SulfateTable 1. Summary of the Synthetic Polysaccharides and the Results of Their Bindings to Antithrombin
Compounds Modification Enzymes Structural Featuresa
O-35S-Labeled
Sulfation Level
(nmoles /mg
Polysaccharide)
Binding to
Antithrombin
Affinity
Column (%)b
Binding
Constant to
Antithrombin
(KD) (nM)
c
1 2-OST, 6-OST-1, 6-OST-3,
and 3-OST-1
No iduronic acid residue 1.4 51% 27 nM
2 6-OST-1, 6-OST-3,
and 3-OST-1
No iduronic acid residue;
no 2-O-sulfation
1.1 52% 57 nM
3 3-OST-1 and 2-OST No iduronic acid residue;
no 6-O-sulfation
0.9 1.0% Not determined
4 Epi, 2-OST, and 3-OST-1 No 6-O-sulfation 1.3 0.7% Not determined
5 Epi, 2-OST, 6-OST-1,
and 6-OST-3
No 3-O-sulfation 1.5 0.6% Not determined
6 Epi and 3-OST-1 No 2-O- and 6-O-sulfations 0.4 5.1% Not determined
7 Epi, 6-OST-1, 6-OST-3,
and 3-OST-1
No 2-O-sulfation 1.3 29% 25 nM
8 Epi, 6-OST-1, 6-OST-3,
3-OST-1, and 2-OST
Very similar to the HS
isolated from tissues
1.5 35% 29 nM
Epi, C5-epimerase.
a These structural features are compared to heparin and HS isolated from natural sources.
b The percentage of the 35S-labeled polysaccharide bound to the AT-affinity column was determined by incubating AT and the
polysaccharides. The complex of AT and polysaccharide was captured by using a ConA-agarose column.
c The binding affinity of the polysaccharides and AT was determined by using affinity coelectrophoresis.2, 7, and 8 bound to AT, while 3, 4, 5, and 6 showed much
less or no binding to AT (Table 1). We noted that 1, 2, 7 and
8 all carry 3-O- and 6-O-sulfo groups, while 3, 4, 5, and 6
either lacked 3-O-sulfo or 6-O-sulfo groups. Thus, we
concluded that both 3-O-sulfation and 6-O-sulfation of
the glucosamine unit are critical for binding to AT. In addi-
tion, 2-O-sulfation of IdoUA is not essential, provided that
7 binds to AT. These conclusions are largely consistent
with previously published results of chemically synthe-
sized pentasaccharides [20] as well as enzymatically syn-
thesized polysaccharides [12, 21]. The binding constants
(KDs) of the synthetic polysaccharides and AT were deter-
mined to be in the range of 27–57 nM (Table 1), which are
very similar to that of previously characterized anticoagu-
lant HS [17].
The synthetic polysaccharides displayed excellent anti-
coagulant activity, asmeasured by anti-Xa and anti-IIa ac-
tivities (Table 2). The IC50 values of compounds 1, 2, 7, and
8 for Xa are 2- to 2.5-fold higher than that of unfractionated
heparin, while they are about 2-fold lower than that of
Lovenox, a low-molecular weight heparin drug manufac-
tured by Aventis. A similar trend was observed for the
anti-IIa activity of these compounds. The N-sulfo heparo-
san 6-O-sulfate was used as a negative control and
showed no inhibitory effect on the activity of Xa and IIa.
Among the synthesized AT-binding polysaccharides,
compound 2 has the simplest structure because it should
contain neither IdoUA nor 2-O-sulfo groups. To further
elucidate the structure of the synthesized polysaccha-
rides, we conducted the disaccharide analysis of com-
pound 2 and compared it to the disaccharide composition988 Chemistry & Biology 14, 986–993, September 2007 ª2007of compound8. The resultant disaccharideswere resolved
on reverse-phase ion pairing (RPIP) HPLC (Figure 2). In-
deed, six disaccharides were observed in compound 8,
while only three disaccharides were observed in com-
pound 2. In addition, we noted that the ratio of the three
disaccharides in 2, including GlcUA-AnMan3S, GlcUA-
AnMan6S, and GlcUA-AnMan3S6S, is about 1:2:1 (Table
3), suggesting that this polysaccharide consists of a
repeating tetrasaccharide unit with a structure of -GlcUA-
GlcNS6S-GlcUA-GlcNS3S ± 6S-. The results from disac-
charide analysis also concluded that the IdoUA residue is
not important for the polysaccharide to bind to AT.
Table 2. Anti-Xa and Anti-IIa Activities of the
Synthetic Polysaccharides
Compounds
Anti-Xa Activity,
IC50 (ng/ml)
Anti-IIa Activity,
IC50 (ng/ml)
Heparin 25 8
1 50 18
2 50 20
7 45 16
8 40 15
N-sulfo heparosan
6-O-sulfatea
>5000 >3000
Lovenoxb 90 50
a The synthesis of N-sulfo heparosan 6-O-sulfate is displayed
in Figure S2.
b Lovenox was purchased from a local pharmacy.Elsevier Ltd All rights reserved
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to AT and strong anticoagulant activity appeared to be
contradictory to previously published results. The IdoUA
residue has been implicated to be essential for the binding
to AT because it provides conformational flexibility [22]. In
the pentasaccharides, the IdoUA residue exists in either
a chair (1C4) or a skew boat (
2S0) conformation [22]. Fur-
thermore, the unique skew boat (2S0) of IdoUA2S in a syn-
thetic pentasaccharide was proved to be essential for the
binding to AT [23]. We believe that the degree to which
conformational flexibility is necessary for AT-binding affin-
ity is size dependent. To test this hypothesis, we com-
pared the AT-binding oligosaccharides’ synthetic
efficiency by using a mixture of enzymes with or without
the capability of synthesizing IdoUA2S. In one prepara-
tion, the oligosaccharides (for the synthesis of oligosac-
charides without the IdoUA2S residue) were incubated
with a mixture of enzymes containing 6-OST-1, 6-OST-3,
and 3-OST-1. In another preparation, the oligosaccha-
Figure 2. RPIP-HPLC Chromatograms of the Disaccharide
Analysis of Compounds 8 and 2
(A and B) The 35S-labeled polysaccharides were degraded by nitrous
acid at pH 1.5, followed by sodium borohydride reduction. The resul-
tant 35S-labeled disaccharides were desalted on a BioGel P-2 column,
and then resolved by reverse-phase ion pairing HPLC chromatogra-
phy. The elution positions were identified by coeluting with 35S-labeled
or 3H-labeled disaccharide standards; 1 represents GlcUA-AnMan3S,
2 represents IdoUA2S-AnMan, 3 represents GlcUA-AnMan6S, 4 rep-
resents IdoUA-AnMan6S, 5 represents IdoUA-AnMan3S6S, 6 repre-
sents GlcUA-AnMan3S6S, and 7 represents IdoUA2S-AnMan6S.Chemistry & Biology 14, 986–99rides (for the synthesis of oligosaccharides with the
IdoUA2S residue) were incubated with a mixture of en-
zymes containing epimerase and 2-OST aswell as 6-OST-
1, 6-OST-3, and 3-OST-1. The oligosaccharide substrates
with structures of DUA-(GlcNS-GlcUA)n-GlcNS-, where
n = 0, 1, 2, 3, 4, and R 5, were prepared by subjecting
N-sulfo heparosan to partial depolymerization with hepa-
rin lyase III, followed by fractionation on gel permeation
chromatography (Figure S1; see the Supplemental Data
available with this article online). After the modifications,
the AT-binding, 35S-labeled oligosaccharides were cap-
tured by the AT-affinity column, and the data are shown in
Figure 3. In the absence of epimerase and 2-OST, 35S-la-
beled octa- and decasaccharides showed substantial
binding to AT, while 35S-labeled hexasaccharide showed
a very low yield. In contrast, when using the same oligo-
saccharide substrates in the presence of epimerase and
2-OST, 35S-labeled hexasaccharides displayed signifi-
cant binding to AT. We noted that the amount of AT-bind-
ing hexasaccharides and octasaccharides is about 4- to
5-fold higher than when the substrates were modified
with a mixture of enzymes containing epimerase and 2-
OST. These results suggest that the contribution of the
IdoUA2S to the AT-binding affinity may be less essential
when the size of the oligosaccharides is larger than an
octasaccharide.
Heparin and HS form a ternary complex with fibroblast
growth factors (FGFs) and fibroblast growth factor recep-
tors (FGFRs) to stimulate cell proliferation; however, this
interaction clearly is not related to the anticoagulant activ-
ity of HS. Here, we tested whether the synthetic polysac-
charides permit the separation of the anticoagulant activ-
ity and cell proliferation activity by using a BaF3 cell model
system. The BaF3 cells overexpressing FGFR1 normally
depend on IL-3 for growth. In the absence of IL-3, cell pro-
liferation depends on the addition of both FGF and heparin
or HS [24]. The cells receiving heparin and compound 8
showed an increase in [3H]thymidine incorporation (Fig-
ure 4). Compound 8 stimulatedBaF3cell growth to a lesser
extent than heparin since its structure is closer to HS than
heparin [7]. We also found that compound 1 showedmod-
est activity in stimulating cell proliferation. Compounds
2 and 7 had no detectable activity in stimulating cell
Table 3. Compositional Analysis of Compounds 2 and 8
Disaccharides
Compound
2 (mol/mol %)
Compound
8 (mol/mol %)
GlcUA-AnMan3S 24.7% N.D.a
IdoUA2S-AnMan N.D. 35.9%
GlcUA-AnMan6S 48.8% 23.3%
IdoUA-AnMan6S N.D. 15.9%
IdoUA-AnMan3S6S N.D. 2.2%
GlcUA-AnMan3S6S 26.2% 8.9%
IdoUA2S-AnMan6S N.D. 13.4%
aNot detectable.3, September 2007 ª2007 Elsevier Ltd All rights reserved 989
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rated the anticoagulant activity and cell proliferation activ-
ity by removing IdoUA2S and IdoUA residues from the
polysaccharide.
The excellent activity and less structural heterogeneity
of compound 2 led us to conduct the synthesis on a larger
scale. We repeated the synthesis of 2 from deacetylated
heparosan by using sequential modifications withN-sulfo-
transferase (NST), 6-OST-1, 6-OST-3, and 3-OST-1 as
described in Figure S2. In this synthesis, we employed a
30-phosphoadenosine 50-phosphosulfate (PAPS) regener-
ation system that used p-nitrophenol sulfate (PNPS) as
a sulfo donor in place of PAPS; this substitution potentially
reduces the cost of the synthesis by more than 1000-fold
[7, 25]. Disaccharide analysis on the intermediate com-
pounds, including N-sulfo heparosan and N-sulfo heparo-
san 6-O-sulfate, revealed that N-sulfation reached 75.6%
and that 6-O-sulfation reached 85% (Table S1). The 3-O-
sulfation carried out by 3-OST-1 went to about 90% com-
pletion, and it was estimated to be 0.5 3-O-sulfo groups/
disaccharide based on the modification with 35S-labeled
PAPS. The final product, renamed recomparin (for re-
combinant heparin), showed anti-Xa activity at the IC50
value of 25 ng/ml, which is very close to the value of hep-
arin (19 ng/ml) (Figure S3). Taken together, our results
show that the enzyme-based approach is fully capable
of synthesizing milligram amounts of this anticoagulant
polysaccharide.
In summary, we report a novel, to our knowledge, ap-
proach to prepare HS polysaccharides with different sul-
Figure 3. Enzymatic Synthesis of AT-Binding Oligosaccha-
rides
The oligosaccharide substrates (1 mg) or the full-length N-sulfo hepar-
osan (1 mg) were incubated with a mixture of enzymes, including
6-OST-1 (20 mg), 6-OST-3 (20 mg), 3-OST-1 (10 mg), and 35S-labeled
PAPS (30 mM, 285,000 cpm/nmole) at 37C for 2 hr. Alternatively, the
oligosaccharides (1 mg) or full-length N-sulfo heparosan (1 mg) were
preincubated with epimerase (8 mg) at 37C for 30 min, followed by
incubation with a mixture of 6-OST-1 (20 mg), 6-OST-3 (20 mg),
2-OST-1 (40 mg), and 3-OST-1 (10 mg) in the presence of 35S-labeled
PAPS. The resultant 35S-labeled oligosaccharideswere incubatedwith
AT, and the complex of AT and 35S-labeled oligosaccharides was cap-
tured by a ConA-agarose column. The amount of 35S-labeled products
with full-length N-sulfo heparosan was defined to be 100%.990 Chemistry & Biology 14, 986–993, September 2007 ª2007 Efation patterns. The compounds are used to investigate
the contribution of the distribution of the sulfo groups to
the biological functions. Utilizing the in vitro HS biosyn-
thetic system, we can prepare a variety of HS structures
by including or excluding certain enzymes. Unlike the
chemical sulfonation approach, our method permits the
synthesis of polysaccharides that are restricted by certain
types of sulfations due to the high substrate specificities of
the sulfotransferases. More importantly, this approach
permits the synthesis of biologically active polysaccha-
rides that may mimic the action of HS under physiological
conditions. Using this approach, we have found that anti-
coagulant polysaccharides do not require the IdoUA resi-
due. The characterization of the precise structure of the
anticoagulant without IdoUA is currently underway. We
hope that this structure will aid in the simplification of
the synthesis of anticoagulant drug with reduced unto-
ward effects. Due to the versatility and flexibility of the en-
zymatic synthesis, this approach will become an increas-
ingly important tool for identifying the lead structures for
the development of HS-based therapeutic agents.
SIGNIFICANCE
Heparan sulfate (HS) is a major component on the
mammalian cell surface and in the extracellular matrix
and has a wide range of biological functions. There is
considerable interest in developing HS-based drugs
to inhibit tumor growth, bacterial viral infections, and
bacterial infections and to modulate inflammatory
responses. It is clear that an enzymatic approach is
a viable method for generating the polysaccharides
with different sulfation patterns and biological func-
tions. The synthesis can be conducted in parallel to
Figure 4. The Effect of the Synthetic Polysaccharides on
FGF2-Dependent BaF3 FGFR1c Cell Proliferation
BaF3 FGFR1c cells were seeded in 96-well plates with 2 nM FGF2 for
control and 2 nM FGF2 plus various concentrations of synthetic poly-
saccharides and heparin. Cells were cultured for 40 hr, followed by
incubation in the media containing [3H]thymidine for 4 hr. The cellular
proliferation was determined by [3H]thymidine incorporation into the
DNA.lsevier Ltd All rights reserved
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levels of individual enzymes. The next challenge for
HS/heparin research is thedevelopmentof a technique
to prepare ‘‘recombinant polysaccharides’’ with more
precise structures so as to achieve high functional
selectivity. In the coming years of the glycomics era,
continuing efforts to improve the enzymatic synthesis
of HSwill lead to the development of novel therapeutic
reagents.
EXPERIMENTAL PROCEDURES
Expression of HS Biosynthetic Enzymes
Expression of HS biosynthetic enzymes, including NST, epimerase,
2-OST, 6-OST-1, and 3-OST-1, was carried out in E. coli as described
previously [7, 26–28]. The expression of 6-OST-3 was also carried out
in E. coli. Briefly, the catalytic domain of mouse 6-OST-3 (Pro121–
Pro450) was cloned into a pMalc2x vector (New England BioLab)
from a mouse brain Quick clone cDNA library (BD Biosciences). The
expression was carried out in Origami-B cells (Novagen) carrying
pGro7 (Takara, Japan) plasmid expressing chaperonin proteins GroEL
and GroES of E. coli. Transformed cells were grown in 6 l LB medium
supplemented with 2mg/ml glucose, 12.5 mg/ml tetracycline, 15 mg/ml
kanamycin, 35 mg/ml chloramphenicol, and 50 mg/ml carbenicillin at
37C. When the A600 reached 0.4–0.7, isopropyl-thiogalactopyrano-
side (0.15 mM) and L-arabinose (1 mg/ml) were added to induce the
expression of 6-OST-3 and chaperonin proteins, respectively. The
cells were allowed to shake overnight at 22C. Purification was carried
out with an amylose-agarose (New England BioLab) column by follow-
ing the protocols provided by manufacturer.
Preparation of Enzymatically Modified Polysaccharides
N-sulfo heparosan was prepared by incubating chemically deacety-
lated heparosan with purified NST and the components of the PAPS
regeneration system described below. N-sulfo heparosan (150 mg)
was incubated with 35S-labeled PAPS (120 mM, 4.53 103 cpm/nmole)
and the combination of epimerase (2.7 mg if included), 2-OST (8 mg if
included), 6-OST-1 (1.2 mg if included), 6-OST-3 (1.4 mg if included),
and 3-OST-1 (0.9 mg if included) in 50 mM MES and 1% Triton X-100
(pH 7.0). The reactions were incubated at 37C for 2 hr with shaking.
The resultant 35S-labeled polysaccharides were purified by DEAE
chromatography [7].
To prepare the enzymatically modified oligosaccharides, the N-35S-
labeled sulfo oligosaccharide substrates (1 mg, 1,500 cpm) were incu-
bated with a mixture of 6-OST-1 (20 mg), 6-OST-3 (20 mg), 3-OST-1
(10 mg), and 35S-labeled PAPS (50 mM, 2.85 3 105 cpm/nmole) in
100 ml 50 mM MES and 1% Triton X-100. Alternatively, the oligosac-
charide substrates (1 mg) were incubated with epimerase (7 mg) at 37C
for 30 min before they were incubated with a mixture of 2-OST (40 mg),
6-OST-1 (20 mg), 6-OST-3 (20 mg), and 3-OST-1 (10 mg). The reactions
were terminated by heating at 100C for 2 min. The resultant oligosac-
charides were mixed with AT to determine binding by using a conca-
navalin A (ConA)-agarose column as described below.
Disaccharide Analysis of Polysaccharides
The 35S-labeled HSwas degraded with nitrous acid at pH 1.5, followed
by reduction with sodium borohydride [29]. The resultant 35S-labeled
disaccharides were resolved by a C18 reverse-phase column (0.46 3
25 cm) (Vydac) under reverse-phase ion pairing HPLC conditions.
The identities of the disaccharides were determined by coeluting
with appropriate 35S-labeled disaccharide standards [30].
Determination of the Amount of Polysaccharides
The amount of the synthetic polysaccharides was estimated by a col-
orimetric method with alcian as described [31]; in this method, the
standard curve was generated by using HS isolated from bovineChemistry & Biology 14, 986–9kidney. To measure the concentrations of heparosan, N-sulfo heparo-
san, and N-sulfo heparosan 6-O-sulfate, the polysaccharides were
depolymerized to disaccharides by using a mixture of heparin lyases
I, II, and III. The amount of the resultant disaccharides was determined
by coeluting with disaccharide standards (from Seikagaku) on RPIP-
HPLC as described above, by using UV 232 nm detection.
Antithrombin Binding
Approximately 1 3 105 cpm 35S-labeled compound was incubated
with 5 mg human AT (Cutter Biological) in 50 ml binding buffer contain-
ing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Mn2+, 1 mM Mg2+,
1 mM Ca2+, 10 mM dextran sulfate, 0.0004% Triton X-100, and 0.02%
sodium azide for 30 min at room temperature. ConA-Sepharose
(Sigma, 50 ml 1:1 slurry) was then added, and the reaction was shaken
at room temperature for 1 hr. The beads were then washed three times
in 1 ml binding buffer, and the bound polysaccharide was eluted with
1 ml 1 M NaCl.
Anti-Xa and Anti-IIa Assays
Assays were based on two previously described methods [32, 33].
Briefly, factor Xa (Enzyme Research Laboratories, South Bend, IN)
and thrombin (Sigma) were diluted to 1 U/ml and 8 U/ml, respectively,
with PBS containing 1mg/ml BSA. AT was diluted with PBS containing
1 mg/ml BSA to give a stock solution at the concentration of 27 mM.
The chromogenic substrates S-2765 (for factor Xa assay) and S-
2238 (for thrombin assay) were purchased from Diapharma and pre-
pared at 1 mM with PBS. The synthesized polysaccharides or heparin
was dissolved in a buffer containing 50 mM Tris-HCl (pH 8.4), 7.5 mM
Na2EDTA,and175mMNaClat variousconcentrations (1–10,000ng/ml).
The reaction mixture, which consisted of 25 ml AT stock solution and
25 ml of the solution containing polysaccharide, was incubated at 37C
for 2min. FactorXa (25ml) or thrombin (25ml)wasadded.After incubating
at 37C for 4min, 25ml S-2765orS-2238was added. Theabsorbanceof
the reaction mixture was measured at 405 nm continuously for 10 min.
The absorbance valueswereplotted against the reaction time. The initial
reaction rates as a function of concentration were used to calculate the
IC50 values.
Affinity Coelectrophoresis
The dissociation constant (KD) of each sample and AT was determined
by using affinity coelectrophoresis [34]. Approximately 4000–5000
cpm antithrombin-binding, 35S-labeled polysaccharide was loaded
per lane; there were zones of AT at concentrations of 0, 8, 16, 60,
and 120 nM. The gel was run at 400 mA for 2 hr, dried, and then ana-
lyzed on a PhosphoImager (Amersham Biosciences, Storm 860). The
retardation coefficient was calculated at R = (M0  M)/M, where M0
is the mobility of the polysaccharide through the zone without AT,
and M is the mobility of the polysaccharide through each separation
zone. The retardation coefficient was then plotted against the retarda-
tion coefficient divided by its respective concentration of AT. The slope
of the line represents 1/KD.
FGF2/FGFR1c-Mediated Proliferation Assay
The BaF3 cells ectopically expressing FGFR1c have been described
previously [24]. The BaF3 FGFR1c cells were maintained in RPMI
1640 media (Sigma, St. Louis, MO) supplemented with 10% fetal
bovine serum, 0.5 ng/ml IL-3 (PeproTech, Inc., Rocky Hill, NJ), 2 mM
L-glutamine, penicillin (50 IU/ml), and streptomycin (50 mg/ml), and
50 mM b-mercaptoethanol. For mitogenic assays, BaF3 FGFR1c cells
were washed three times with RPMI 1640 media to remove IL-3 and
resuspended in the growth media lacking IL-3. About 30,000 cells
were plated per well in a 96-well plate in media containing various
concentrations of heparin, compounds 1, 2, 7, and 8, and 2 nM FGF2
(PeproTech, Inc.) in a total volume of 200 ml. The cells were then incu-
bated at 37C for 40 hr. To each well, an additional 50 ml growth media
containing 1 mCi [3H]thymidine was added. Cells were harvested after
4–5 hr by centrifugation. The incorporation of [3H]thymidine into the
DNA was determined by scintillation counting.93, September 2007 ª2007 Elsevier Ltd All rights reserved 991
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The reactions involved in the PAPS regeneration system are shown in
Figure S2. N-terminal His6-tagged AST-IV was expressed in E. coli and
purified as described by Burkat and colleagues [25] at a yieldz50mg/l
bacterial culture.
Preparation of N-Sulfo Heparosan
Heparosan was isolated from E. coli K5 strain by using a DEAE column
[35]. The deacetylated heparosan was achieved under alkaline condi-
tions [36]. The deacetylated heparosan was incubated with purified
NST and coupledwith a PAPS regeneration system. Briefly, 2.5mg pu-
rified AST-IV was incubated with 40 mM PAP and 1 mM p-nitrophenol
sulfate (PNPS) in 40 ml 50 mM MES (pH 7.0), 1% Triton X-100, 1 mM
MgCl2, and 1 mM MnCl2 at 25
C for 15 min. The reaction mixture
was mixed with N-sulfotransferase (10 mg), 5 mg deacetylated hepar-
osan was added, and the mixture was rotated at 25C for 24 hr. The
N-sulfo heparosan was recovered by a DEAE column. The resultant
product was subjected to a mixture of heparin lyases, followed by a di-
saccharide analysis to assess the level ofN-sulfation. After two rounds
of the modifications, the N-sulfation level reached 80%.
Preparation of N-Sulfo Oligosaccharides
N-35S-labeled sulfo heparosan (1 mg, 1.5 3 106 cpm) was mixed with
20 ng purified heparin lyase III in 1 ml 50 mM sodium phosphate (pH
7.0). The digestion lasted for 18 hr and was terminated by heating at
100C for 2 min. The digested polysaccharide was resolved on a Bio-
Gel P-10, which was eluted with a buffer containing 25 mM Tris and
1000 mM NaCl (pH 7.4) at a flow rate of 2 ml/hr.
Supplemental Data
Supplemental Data include the preparation and characterization of re-
comparin and are available at http://www.chembiol.com/cgi/content/
full/14/9/986/DC1/.
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